MedTrace Logo

Multi-omics Model for Pancreatic Cancer Screening Using cfDNA

NCT06456281 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2024-07-01

No results posted yet for this study

Summary

This is a prospective case-control study, aiming at developing a cell free DNA (cfDNA) multi-omics precise diagnostic model for screening of pancreatic cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

A noninvasive cfDNA multi-omics assay

Peripheral venous blood samples will be collected from pancreatic cancer patients, individuals with precancerous lesions, and healthy controls. Subsequently, cfDNA will be extracted and subjected to low-pass whole genome sequencing (LP-WGS) and hybrid capture-based targeted methylation sequencing (TMS).

Sponsors & Collaborators

  • Nanjing Simcere Medical Laboratory Science Co., Ltd.

    collaborator UNKNOWN

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-28
Primary Completion
2025-03-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06456281 on ClinicalTrials.gov